Systemic antibiotics, primarily neomycin, have also been employed to reduce bacterial production of
ammonia, but associated adverse events
limit their use in patients with hepatic encephalopathy. The semisynthetic, nonsystemic antibiotic, rifaximin, was approved in March 2010 by the United States Food and Drug Administration for the treatment of overt hepatic encephalopathy.